array(3) { ["company_details"]=> array(13) { ["name"]=> string(13) "Pharming B.V." ["slug"]=> string(20) "00474-nl-pharming-bv" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/6f06b060-b806-43f2-addd-a605083bf776" ["description"]=> string(987) "Pharming is a global biopharmaceutical company that develops and commercializes innovative protein replacement therapies and precision medicines for rare diseases. They are committed to being a sustainable partner for all stakeholder groups, including patients, healthcare professionals, employees, and shareholders. Pharming is headquartered in Leiden, the Netherlands, with its U.S. headquarters in Warren, New Jersey. They are listed on the Amsterdam Euronext and Nasdaq exchanges. Their vision is to become the leading global rare disease company and their mission is to bring solutions to unserved rare disease patients through drug development and commercialization. They aim to transform their pipeline to include multiple commercialized products in multiple geographies and to expand their technology portfolio. The company culture at Pharming emphasizes teamwork, self-development, and results orientation. They participate in investor conferences and provide financial updates." ["address_street"]=> string(12) "Darwinweg 24" ["address_place"]=> string(6) "Leiden" ["address_region"]=> NULL ["founding_date"]=> NULL ["website_domain"]=> string(12) "pharming.com" ["website_url"]=> string(24) "https://www.pharming.com" ["industry_codes"]=> array(1) { [0]=> string(75) "Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified" } ["employee_count"]=> NULL ["article_count"]=> int(55) } ["articles"]=> array(2) { [0]=> array(7) { ["title_en"]=> string(70) "Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price" ["snippet_en"]=> string(122) "With a price-to-sales (or "P/S") ratio of 3.4x Pharming Group N.V. ( AMS:PHARM ) may be sending very bullish signals at..." ["url"]=> string(153) "https://simplywall.st/stocks/nl/pharmaceuticals-biotech/ams-pharm/pharming-group-shares/news/revenues-working-against-pharming-group-nvs-amspharm-share-p" ["image_url"]=> string(78) "https://images.businessradar.com/articles/fe08ec05-c725-4afc-b7ee-d83ae48c4c6d" ["source"]=> string(13) "simplywall.st" ["publication_date"]=> string(10) "2024-02-14" ["categories"]=> array(3) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(12) "Stock Market" [2]=> string(15) "Market Movement" } } [1]=> array(7) { ["title_en"]=> string(39) "Pharming Turbo Long 0.65 » Turbo price" ["snippet_en"]=> string(181) "The price of Pharming Turbo Long 0.65 (Turbo, PSE) with news items, columns, agenda, forum, technical analysis, fundamental analysis, options, turbos, speeders, sprinters and advice" ["url"]=> string(86) "https://www.iex.nl/Societe-Generale-Turbo-Koers/600422403/Pharming-Turbo-Long-065.aspx" ["image_url"]=> string(78) "https://images.businessradar.com/articles/9c009370-9e92-4309-a56d-7dd87d7f6de7" ["source"]=> string(6) "iex.nl" ["publication_date"]=> NULL ["categories"]=> array(2) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(12) "Stock Market" } } } ["category_annotations"]=> array(28) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(13) } [1]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(8) } [2]=> array(2) { ["name"]=> string(10) "Insolvency" ["count"]=> int(4) } [3]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(4) } [4]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(3) } [5]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(3) } [6]=> array(2) { ["name"]=> string(21) "Financial Performance" ["count"]=> int(2) } [7]=> array(2) { ["name"]=> string(9) "Investors" ["count"]=> int(2) } [8]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(2) } [9]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(2) } [10]=> array(2) { ["name"]=> string(10) "Executives" ["count"]=> int(1) } [11]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(1) } [12]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(1) } [13]=> array(2) { ["name"]=> string(24) "Government Interventions" ["count"]=> int(1) } [14]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(1) } [15]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(1) } [16]=> array(2) { ["name"]=> string(21) "Shareholders Feedback" ["count"]=> int(1) } [17]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(1) } [18]=> array(2) { ["name"]=> string(9) "Valuation" ["count"]=> int(1) } [19]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(1) } [20]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(1) } [21]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(1) } [22]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(1) } [23]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(1) } [24]=> array(2) { ["name"]=> string(5) "Debts" ["count"]=> int(1) } [25]=> array(2) { ["name"]=> string(19) "Economic Conditions" ["count"]=> int(1) } [26]=> array(2) { ["name"]=> string(7) "Economy" ["count"]=> int(1) } [27]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(1) } } } 00474-nl-pharming-bv